EZH2 and diffuse large B-cell lymphoma: Mutations in genes responsible for histone and chromatin modifications, such as CREBBP, KMT2D, EZH2, and TET2, drive aberrant epigenetic B cell programming and influence DLBCL clinical outcome [53].